NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
SRF to Invest Rs 180 Crore for New Pharma Intermediate Plant at Dahej
SRF Limited has announced a capital expenditure of Rs 180 crore for setting up a new Pharma Intermediate Plant (PIP-2) at its Dahej site in Gujarat. The facility will focus on precursor processes for pharmaceutical products to capture emerging business opportunities in the pharma sector. The project is expected to be completed by September 30, 2026. The investment will be funded through a mix of debt and internal accruals, reflecting the company's focus on high-growth specialty segments.
முக்கிய அம்சங்கள்
Board approved Rs 180 crore investment for a new Pharma Intermediate Plant (PIP-2)The plant will be located at Dahej, Gujarat, focusing on pharma precursor processesProjected completion date for the new facility is September 30, 2026Funding will be managed through a combination of debt and internal accruals
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step towards diversifying and strengthening SRF's specialty chemicals and pharma portfolio. Monitor the project's progress toward the 2026 deadline as it represents a key driver for long-term margin expansion.
SRF Limited Appoints Samir Kashyap as President & CFO Effective January 27, 2026
SRF Limited has announced the appointment of Mr. Samir Kashyap as its President and Chief Financial Officer (CFO), effective January 27, 2026. Mr. Kashyap is a seasoned professional with over 30 years of experience, including 20 years as a CFO at major global firms such as Meta, SAP, and Genpact. His background includes expertise in financial planning, M&A integration, and digital transformation across emerging and developed markets. This strategic appointment aims to bolster SRF's financial leadership and corporate governance.
முக்கிய அம்சங்கள்
Samir Kashyap appointed as President & CFO starting January 27, 2026Brings over 30 years of total experience, with 20 years in CFO roles at Meta, SAP, and GenpactExpertise spans financial planning, M&A integration, digital transformation, and corporate governanceEducational background includes a B.Com (H) from SRCC and a Chartered Accountancy (CA) degree
👀 கவனிக்க வேண்டியவை
Investors should view this high-profile appointment positively as it brings global financial expertise to the company. Monitor for any strategic shifts in capital allocation or financial reporting under the new leadership.
SRF Q3 FY26 Results: PAT Surges 60% YoY to ₹433 Cr Driven by Chemicals Segment
SRF Limited reported a strong performance for Q3 FY26, with consolidated revenue growing 6.3% YoY to ₹3,712.5 crore and Profit After Tax (PAT) jumping 59.6% to ₹432.7 crore. The Chemicals business was the primary driver, with segment revenue increasing 22% and EBIT rising 36.4% due to higher volumes in Fluorochemicals. However, the Packaging Films and Technical Textiles segments faced headwinds, with revenues declining 3.1% and 11% respectively due to pricing pressure and Chinese competition. The company also announced a new ₹180 crore capex for a Pharma Intermediates plant at Dahej to bolster its specialty chemicals portfolio.
முக்கிய அம்சங்கள்
Consolidated PAT increased by 59.6% YoY to ₹432.7 crore, while EBITDA margins expanded to 22.8% from 19.9%.Chemicals segment revenue grew 22% YoY to ₹1,824.8 crore, contributing 76% of the total EBIT.Board approved a ₹180 crore investment for a new Pharma Intermediates Plant at Dahej to drive future growth.Performance Films & Foil segment EBIT grew 4.9% despite a 3.1% revenue dip, aided by strong performance in South Africa.Technical Textiles revenue fell 11% YoY to ₹453.6 crore due to margin pressure from Chinese imports and US tariffs.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong recovery in the Chemicals segment and the company's strategic shift toward high-value pharma intermediates. While packaging films face global competition, the overall margin expansion and robust capex pipeline support a positive long-term outlook.
SRF Q3FY26 PAT Surges 60% to ₹433 Cr; Declares ₹5 Interim Dividend & ₹180 Cr Capex
SRF reported a strong Q3FY26 with PAT growing 60% YoY to ₹433 crore, primarily driven by a 36% jump in operating profit within the Chemicals segment. While the Fluorochemicals division saw record performance due to firm global HFC prices, the Specialty Chemicals and Technical Textiles segments faced headwinds from aggressive Chinese pricing. The company announced a second interim dividend of ₹5 per share and approved a ₹180 crore investment for a new Pharma Intermediates plant. Despite a ₹73 crore one-time impact from new labour codes, the overall bottom-line growth remains robust.
முக்கிய அம்சங்கள்
Consolidated PAT increased 60% YoY to ₹433 crore, while revenue grew 6% to ₹3,713 crore.Chemicals Business EBIT rose 36% to ₹496 crore, led by strong refrigerant gas demand and pricing.Board approved a second interim dividend of ₹5 per share and a ₹180 crore capex for a Pharma Intermediates facility.Technical Textiles revenue fell 11% YoY due to Chinese competition and lower exports to the US.9M FY26 PAT stands at ₹1,253 crore, a significant 73% increase over the previous year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong recovery in the Fluorochemicals segment and the company's continued expansion into Pharma intermediates. The stock remains a solid play on the specialty chemicals recovery, though Chinese pricing pressure in other segments warrants monitoring.
SRF Declares Second Interim Dividend of Rs 5 Per Share for FY 2025-26
SRF Limited has announced its second interim dividend for the financial year 2025-26 at Rs 5 per equity share, which is 50% of the paid-up capital. The Board of Directors finalized this decision during their meeting on January 20, 2026. Shareholders appearing on the register as of the record date, January 27, 2026, will be eligible for the payout. The company expects to complete the dividend distribution by February 17, 2026.
முக்கிய அம்சங்கள்
Interim dividend declared at Rs 5.00 per equity share (50% payout)Record date for determining eligibility is Tuesday, January 27, 2026Dividend payment to be completed on or before February 17, 2026This marks the second interim dividend distribution for the current fiscal year
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the shares before the record date of January 27, 2026. The payout reflects the company's consistent policy of sharing profits with shareholders.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
SRF Q3 FY26 Standalone PAT Jumps 63.6% YoY to ₹457.91 Cr; Chemicals Segment Leads Growth
SRF reported a strong performance for the quarter ended December 31, 2025, with standalone revenue growing 6.9% YoY to ₹2,951.68 crore. The bottom line saw a significant boost, with Net Profit rising 63.6% YoY to ₹457.91 crore, aided by a ₹99.12 crore tax adjustment from earlier years. The Chemicals Business remains the primary growth engine, with segment revenue increasing 23.7% YoY to ₹1,861.25 crore. However, the Packaging Films and Technical Textiles segments faced headwinds, reporting YoY revenue declines of 15.6% and 11.0% respectively.
முக்கிய அம்சங்கள்
Standalone Net Profit surged 63.6% YoY to ₹457.91 crore, supported by a ₹99.12 crore tax credit.Chemicals Business revenue grew 23.7% YoY to ₹1,861.25 crore, with segment EBIT rising 51.1% to ₹549.72 crore.Packaging Films revenue declined 15.6% YoY to ₹544.99 crore, reflecting continued margin pressure in the industry.Technical Textiles revenue fell 11.0% YoY to ₹453.58 crore compared to the same period last year.Recognized a one-time exceptional expense of ₹72.95 crore due to the impact of New Labour Codes.
👀 கவனிக்க வேண்டியவை
Investors should focus on the sustained recovery and growth in the high-margin Chemicals segment, which is successfully offsetting weakness in other divisions. The stock remains a strong long-term play on specialty chemicals, though cyclicality in packaging films warrants continued monitoring.
SRF Wins Tax Dispute at ITAT; Tax Liability to Reduce by Rs 99 Crores
SRF Limited has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding the taxation of Carbon Emission Reduction Certificates (CERs). The tribunal ruled that CERs for AY 2011-12 and AY 2013-14 should be treated as capital receipts, making them non-taxable under the Income Tax Act. This outcome is expected to result in a significant reduction of the company's tax liability by approximately Rs 99 Crores. This positive development will likely improve the company's net profit and cash position once the adjustment is accounted for.
முக்கிய அம்சங்கள்
ITAT ruled in favor of SRF regarding the treatment of Carbon Emission Reduction Certificates (CERs).CERs to be treated as capital receipts, exempting them from income tax for AY 2011-12 and AY 2013-14.The ruling results in a reduction of tax liability by approximately Rs 99 Crores.The dispute was against the Assistant Commissioner of Income Tax, New Delhi.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that will provide a one-time boost to the company's bottom line. Monitor if the Income Tax department files a further appeal in the High Court.
SRF: Insider Trading Violations Reported Under SEBI Regulations
SRF Limited reported violations of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Two designated persons, Rama Krishna Putcha and Ganga Singh, violated the company's code of conduct. Mr. Putcha purchased and sold 600 shares on May 15, 2025, and was directed to disgorge profits of ₹8587. Mr. Singh purchased and sold 200 shares on May 27, 2025, and was directed to disgorge profits of ₹1927. Both individuals failed to obtain pre-clearance and delayed reporting the trades.
முக்கிய அம்சங்கள்
Rama Krishna Putcha disgorged ₹8587 for insider trading violation.Ganga Singh disgorged ₹1927 for insider trading violation.Putcha traded 600 shares without pre-clearance on May 15, 2025.Singh traded 200 shares without pre-clearance on May 27, 2025.
👀 கவனிக்க வேண்டியவை
Investors should note the company's efforts to enforce its code of conduct and SEBI regulations. Monitor future filings for any further instances of non-compliance.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
